ReachMD

Be part of the knowledge.™

Oncology - Hematology

14

LikeLikedUnlike

Episodes 16-28 of 28

Integrating Multicancer Early Detection into Clinical Care
Medical Industry Feature
Integrating Multicancer Early Detection into Clinical Care
- Sana Raoof, MD, PhD
  Peer
- Candace T. Westgate, DO, MPH, FACOG
  Peer
- Mylynda Massart, MD, PhD
  Peer
Bispecific Antibody Treatment in Relapsed or Refractory Multiple Myeloma
Medical Industry Feature
Bispecific Antibody Treatment in Relapsed or Refractory Multiple Myeloma
- Jennifer Caudle, DO
  Peer
- Leonid Shunyakov, MD
  Peer
Watch Expert Insights on Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
Medical Industry Feature
Watch Expert Insights on Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
- Ken Shain, MD, PhD
  Peer
Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types in the MAIA Study
Medical Industry Feature
Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types in the MAIA Study
- John Russell, MD
  Peer
- Hana Safah, MD
  Peer
Examining Unmet Needs in Gastric and GEJ Cancer Care and the Role of Emergining Personalized Medicine
Medical Industry Feature
Examining Unmet Needs in Gastric and GEJ Cancer Care and the Role of Emergining Personalized Medicine
- Nataliya Uboha, MD, PhD
  Peer
Pathways to Evolving Personalized Medicine in Gastric and GEJ Cancer: An Overview of Current Established and Emerging Biomarkers
Medical Industry Feature
Pathways to Evolving Personalized Medicine in Gastric and GEJ Cancer: An Overview of Current Established and Emerging Biomarkers
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Kristina Matkowskyj, MD, PhD
  Peer
- Nataliya Uboha, MD, PhD
  Peer
Experts Discuss What the TITAN Trial Means for Managing Patients With mCSPC
Medical Industry Feature
Experts Discuss What the TITAN Trial Means for Managing Patients With mCSPC
- Joelle Hamilton, MD
  Peer
- Michael Fabrizio, MD, FACS
  Peer
- Mahdi Taha, DO
  Peer
Addressing Hesitancy on Biosimilars: From Development to Clinical Practice
Medical Industry Feature
Addressing Hesitancy on Biosimilars: From Development to Clinical Practice
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Jerome Goldschmidt, MD
  Peer
Comparing Targeted Therapies for Wild-Type RAS Metastatic Colorectal Cancer
Medical Industry Feature
Comparing Targeted Therapies for Wild-Type RAS Metastatic Colorectal Cancer
- Jennifer Caudle, DO
  Peer
- Matthew Dugan, DO
  Peer
Inflammation Biosimilars: Examining the Totality of Evidence for Approval
Medical Industry Feature
Inflammation Biosimilars: Examining the Totality of Evidence for Approval
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Gil Melmed, MD, MS
  Peer
Operational Pathways for Biomarker Testing in NSCLC
Medical Industry Feature
Operational Pathways for Biomarker Testing in NSCLC
- Matt Birnholz, MD
  Peer
- David Braxton, MD
  Peer
Investigating Imaging Techniques in Multiple Myeloma
Medical Industry Feature
Investigating Imaging Techniques in Multiple Myeloma
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Jens Hillengass, MD, PhD
  Peer
Key Considerations for G-CSF Administration in Patients with FN Risk
Medical Industry Feature
Key Considerations for G-CSF Administration in Patients with FN Risk
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Arielle Heeke, MD
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended